Sweden’s Sobi agreed to acquire Arthrosi Therapeutics for $950 million cash upfront plus up to $550 million in milestones to add pozdeutinurad (AR882), a Phase III oral URAT1 inhibitor, to its portfolio. Sobi said the asset complements its existing gout franchise and could accelerate growth through the mid-2030s if Phase III data and regulatory filings succeed. Arthrosi’s two global Phase III trials are fully enrolled with topline data expected in 2026. Sobi plans to finance the transaction predominantly through debt facilities and signaled integration of Arthrosi’s team and development plan into its gout strategy. The deal includes regional rights and noted ApicHope holds Greater China rights to the asset. The acquisition underscores continued consolidation in specialty rare-disease and inflammation space, where mid‑stage assets with Phase III readouts are valuable to companies seeking near-term launches. URAT1 inhibitors target renal urate reabsorption; safety and kidney tolerability will be focal points for regulators and clinicians given historical class concerns.